From: Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
Treatment | RPE only | RT only | RT after RPE | |||
---|---|---|---|---|---|---|
N | % | N | % | N | % | |
All | 14289 | 100.0 | 3883 | 100.0 | 1366 | 100.0 |
Age [yrs] | ||||||
median | 65.2 | 70.3 | 64.4 | |||
< 60 | 3208 | 22.5 | 367 | 9.5 | 356 | 26.1 |
60–64 | 3758 | 26.3 | 599 | 15.4 | 364 | 26.6 |
65–69 | 4391 | 30.7 | 903 | 23.3 | 412 | 30.2 |
70–74 | 2432 | 17.0 | 1135 | 29.2 | 199 | 14.6 |
> =75 | 500 | 3.5 | 879 | 22.6 | 35 | 2.6 |
Risk Group | ||||||
low riska | 1843 | 13.2 | 529 | 17.0 | 35 | 2.6 |
intermediate riskb | 3051 | 21.9 | 665 | 21.4 | 162 | 12.1 |
high riskc | 6130 | 44.1 | 1067 | 34.3 | 504 | 37.8 |
locally advancedd | 2615 | 18.8 | 738 | 23.8 | 522 | 39.1 |
advanced (N+) | 275 | 2.0 | 108 | 3.5 | 112 | 8.4 |
metastasized (M1) | 54 | 0.4 | 401 | 11.4 | 20 | 1.5 |
Missing e | 321 | 2.2 | 375 | 9.7 | 11 | 0.8 |
T-category | ||||||
T1 | 1852 | 13.4 | 586 | 19.2 | 146 | 10.9 |
T2 | 9152 | 66.0 | 1508 | 49.5 | 563 | 42.1 |
T3 | 2724 | 19.6 | 784 | 25.7 | 565 | 42.3 |
T4 | 139 | 1.0 | 170 | 5.6 | 62 | 4.6 |
Missing e | 422 | 3.0 | 835 | 21.5 | 30 | 2.2 |
N-category | ||||||
N0 | 9008 | 65.2 | 2046 | 67.3 | 869 | 64.6 |
N+ | 346 | 2.5 | 198 | 6.5 | 128 | 9.5 |
NX | 4460 | 32.3 | 794 | 26.1 | 348 | 25.9 |
Missing e | 475 | 3.3 | 845 | 21.8 | 21 | 1.5 |
M-category | ||||||
M0 | 14235 | 99.6 | 3482 | 89.7 | 1346 | 98.5 |
M1 | 54 | 0.4 | 401 | 10.3 | 20 | 1.5 |
Second Cancer (p < 0.0001) | ||||||
developed | 1876 | 638 | 186 | |||
CI after 10 years | 10.5 | 15.9 | 13.2 | |||
CI after 20 years | 23.7 | 26.7 | 26.6 | |||
Median follow-up of survivors [yrs] (p < 0.0001) | ||||||
10.2 | 9.6 | 8.8 |